Side-by-side comparison of AI visibility scores, market position, and capabilities
Wilmington DE YC W23 AI clinical notes EHR for mental health therapists; $728K total ($500K YC seed Oct 2023) with HIPAA-compliant AI notes and EHR integration competing with SimplePractice for independent therapist documentation.
Orchid is a Wilmington, Delaware-based AI-powered EHR platform for mental health professionals — backed by Y Combinator (W23) with $728,000 in total funding including a $500,000 seed in October 2023 from Y Combinator — providing independent mental health clinicians (therapists, psychologists, counselors) with HIPAA-compliant AI clinical notes that integrate with any existing EHR, automating note-taking to free time for patient care. Launched Orchid AI in July 2024, with e-prescribing planned for 2025, Orchid streamlines the administrative workflows and clinical documentation burden that forces mental health professionals to spend 2-3 hours daily on paperwork that competes with patient care time. Founded in 2020, targeting the solo and small group independent mental health practice market.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.